Close

Surface Oncology to Collaborate with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

Go back to Surface Oncology to Collaborate with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
Surf A Movie Solutions, Inc. (NASDAQ: SURF) Delayed: 1.07 --0 (-0%)
Previous Close $1.07    52 Week High $0.42 
Open $1.07    52 Week Low $0.42 
Day High $1.07    P/E N/A 
Day Low $1.07    EPS $-0.01 
Volume 19,118